A new biomarker may be on the horizon to more accurately identify psychiatric patients who may later develop fulminant psychosis, according to a study published in yesterday's Biological Psychiatry.
Daniel Mathalon, M.D., Ph.D., a professor of psychiatry at the University of California San Francisco, led a study evaluating the amount of mismatch negativity (MMN)—an auditory signaling process that travels to the frontal lobe regions in response to sound—in 101 individuals with a high clinical risk for psychosis, or schizophrenia or no history of mental illness.
Read more on Psychiatric News.
Contact us
675 18th St, 4th Floor
San Francisco, CA 94107
Phone: (415) 476-7278
Email: [email protected]
Email Us
Is the Path Program right for you?
Answer a few confidential questions about your mental health to help determine whether the Path Program or current research opportunities may be a fit for you.
Support Our Work
Medium: Digital collage
We are honored to feature the artwork of participants from our program and similar programs across our website. View more from our recent art show, Extreme states and Everything In Between.
